Aims: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine. Two euglycaemic clamp studies, 1 in subjects with type 1 diabetes (T1D) and 1 in healthy subjects, were conducted to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between MK-1293 and Lantus commercially procured in both the European Union (EU-Lantus) and the USA (US-Lantus).
| INTRODUCTION
Insulin glargine is a recombinant human basal insulin analog produced in Escherichia coli (E. coli) that is marketed worldwide by Sanofi (Paris, France) under the trade name Lantus. Lantus is approved for the treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D). 1, 2 Though Lantus and other approved basal insulin products are effective treatments for patients with T1D and T2D, the cost of these products can present a barrier to patient access. High-quality follow-on basal insulin products, approved for marketing based on rigourous demonstration of similarity to approved reference products, are important treatment options that could increase access for a broader population of patients. The specific terminology applied to follow-on insulin products such as MK-1293 differs among regulatory regions.
They are designated as biosimilars in several regions including the European Union. 3 In the USA, while follow-on insulin products are not currently designated as biosimilars and are developed under a different regulatory pathway, 4 the same principle of establishing similarity to an approved reference product is applied.
Demonstration of similarity between follow-on and approved ref- Study B (PN002) was a double-blind, randomized, single-centre, 3-period complete crossover study in healthy subjects ( Figure S1B ).
| RESEARCH DESIGN AND METHODS

| Study design
In each period, eligible subjects received 1 of 3 single-dose treat- In Study B, subjects were healthy men aged 18 to 45 years, with >80 mL/min based on the Cockroft-Gault equation or 24-hour urine collection. 
| Pharmacokinetic sampling
| Euglycaemic clamping
In both studies, subjects began fasting from 10:00 PM on Day 
| Bioanalytical methods
In both studies, a validated liquid chromatographic-tandem mass spectrometric (LC-MS/MS) detection method, modified from a previously published assay, 7 was used to simultaneously determine concentrations of parent insulin glargine and its 2 bioactive metabolites, M1 and M2. The method was based on an automated 96-well format immunoaffinity purification of analytes of interest from human plasma. Parent glargine, M1, M2 and their corresponding stable isotope-labeled internal standards were chromatographed using reversed phase LC and were detected with tandem mass spectrometric detection using multiple reaction montoring (MRM). The analytical range of quantification was 100 to 10 000 pg/mL for all analytes using 0.5 mL of plasma. All validation and sample quantification runs met the pre-specified acceptance criteria, including incurred sample reproducibility (ISR).
| Pharmacokinetic assessments
As M1 is the major circulating active glargine species after s.c. administration, [7] [8] [9] it was the primary PK analyte. Pharmacokinetic parameters included AUC 0-24 and C max (primary endpoints), as well as Therefore, no PK parameters were calculated for these analytes. 
| Pharmacodynamic assessments
| Safety assessments
Adverse events (AEs) were assessed throughout the 2 studies. All clinical AEs were evaluated in terms of intensity, duration, severity, outcome and relationship to study medication. Other safety parameters, including vital signs, physical examinations, 12-lead electrocardiograms (ECGs), and standard laboratory safety tests, were assessed pre-dose and at various time points post-dose and post-study. AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] were analysed using the same statistical methods as described for M1 AUC 0-24 and C max .
| Pharmacodynamics
To assess glucose concentration variability around the clamp target, a mixed effects model with only a random effect for subject was used to estimate the within-subject glucose variability across time points and periods. Mean ambient glucose concentration and within-subject percent coefficient of variation (% CV) were calculated from the model using glucose concentrations between the initiation of glucose infusion and either the last time glucose was infused during the clamp (Study B) or the last time glucose was infused prior to end of action (Study A).
Individual GIR parameter (GIR-AUC 0-24 , GIR-AUC 0-12 , GIR- 
| Sample size
For both studies, an overall power of 80% to meet all study objectives was targeted. In the Study A protocol, assuming a 2-sided alpha of 0.025 for PD (95% CIs) and 0.05 for PK (90% CIs), and similarity bounds for the primary PK and PD endpoints as noted above, a sample size of 70 completers was predicted to provide at least 80% overall power. In the Study B protocol, assuming a 2-sided alpha of 0.05 (90% CIs) for all primary PK and PD endpoints and the similarity bounds noted above, a sample size of 72 completers was predicted to provide at least 80% overall power. Following the start of each study, an interim analysis for assessment of variance for the primary PK and PD endpoints was conducted to determine whether it was necessary to increase sample size to provide at least 80% overall power to meet all hypotheses. Mean treatment effects were not calculated during the interim analyses. These interim variance assessments were conducted by a pharmacokineticist and a statistician who were blinded to treatment and had no other involvement in these studies. For Study A, no increase in sample size was needed. For Study B, the interim analysis indicated that a sample size of 72 would not have provided at least 80% overall power; therefore, the sample size was increased from 72 to 96 completers. Table 1 . Of the 6 subjects who did not complete the study, 4 were withdrawn because of subject decision, 1 because of glucose infusion error, and 1 because of physician decision as the patient required antibiotic treatment.
| Pharmacokinetics
Mean PK profiles for the M1 glargine metabolite were similar between MK-1293 and EU-Lantus in subjects with T1D ( Figure 1A ). The 90%
CIs for the geometric mean ratios (MK-1293/Lantus) were within 0.80 and 1.25 for both primary PK endpoints (AUC 0-24 and C max ), thereby meeting the pre-specified statistical similarity criterion (Table 2 ). For both secondary PK endpoints of interest (AUC 0-12 and AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ), the 90% CIs for the geometric mean ratios (MK-1293/Lantus) were also within 0.80 and 1.25, although no statistical similarity criteria were pre-specified for these comparisons. Median M1 T max was approximately 12 hours for both treatments. The replicate design of Study A Data are expressed as mean AE SD or n (%).
permitted assessment of within-subject, between-period PK variability.
The within-subject % CV for MK-1293 was consistent with that of EULantus for all primary and secondary PK endpoints.
| Pharmacodynamics
Between the time of dosing and end of action, mean plasma glucose concentration was very close to the clamp target of 130 mg/dL (129.5 mg/dL with a % CV of 5.9%). This is consistent with the reported clamping precision in T1D subjects 10, 11 and confirms that glucose clamping was achieved with a high degree of precision. Mean GIR profiles were similar between MK-1293 and EU-Lantus ( Figure 1B ) and the 95% CIs for the ratios of arithmetic means (MK-1293/Lantus) for all 4 GIR-based primary PD endpoints (GIR-AUC 0-24 , GIR-AUC 0-12 , GIR-AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , GIR max ) were within 0.80 and 1.25, thereby meeting the pre-specified statistical similarity criterion for these endpoints (Table 2) . Median Time to GIR max was approximately 10 to 11 hours across treatments. As with PK, the within-subject % CV for MK-1293 was consistent with that of EU-Lantus for all primary GIR endpoints. For both MK-1293 and Lantus, end of action was not observed during the 30-hour clamping timeframe in the majority of subjects. Both a statistical survival analysis (Table 2 ) and the distribution of DOA ( Figure S2 ) indicated similarity between MK-1293 and EU-Lantus. 
| Healthy subjects (Study B) 3.2.1 | Demographics and disposition
| Pharmacokinetics
Mean PK profiles for the M1 glargine metabolite were similar among all 3 treatments in healthy volunteers ( Figure 1C ). The 90% CIs for the geometric mean ratios (test/reference) for all 3 treatment comparisons were within 0.80 and 1.25 for both primary PK endpoints (AUC 0-24 and C max ), thereby meeting the pre-specified statistical similarity criterion (Table 3) . For both secondary PK endpoints of interest (AUC 0-12 and AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ), the 90% CIs for the geometric mean ratios (MK-1293/Lantus) were also within 0.80 and 1.25 for all 3 treatment comparisons, although no statistical similarity criteria were prespecified for these comparisons. Median M1 T max was 13 to 14 hours across treatments.
| Pharmacodynamics
During the timeframe of active glucose clamping (from initiation to completion of glucose infusion), mean plasma glucose concentration was very close to the clamp target of 80 mg/dL (80.6 mg/dL with a coefficient of variation of 4.7%). This is consistent with the reported clamping precision in similar studies and confirms that glucose clamping was achieved with a high degree of precision. 16, 17 Mean GIR profiles were similar among all treatments ( Figure 1D ). The 90% CIs for the arithmetic mean ratios (test/reference) for all 3 treatment comparisons were within 0.80 and 1.25 for all 4 primary GIR endpoints (GIR-AUC 0-24 , GIR-AUC 0-12 , GIR-AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , GIR max ), thereby meeting the pre-specified statistical similarity criterion (Table 3) . Median
Time to GIR max was approximately 13 hours for all treatments.
3.3 | Safety: Studies A (T1D subjects) and B (healthy subjects)
MK-1293 was generally well tolerated in both studies. No serious adverse events, deaths or discontinuations for safety/tolerability reasons occurred in either study. In each study, similar proportions of subjects reported adverse events after treatment with MK-1293 and the Lantus comparator(s) and all adverse events were mild to moderate in intensity. In Study B (healthy subjects), 8 (7.8%) subjects reported injection-site pain after MK-1293 administration, compared to 5 (5%) and 2 (2%) subjects after US-Lantus and EU-Lantus, respectively. In Study A (T1D subjects), 2 (2.7%) and 1 (1.3%) subjects reported injection-site pain after MK-1293 and EU-Lantus, respectively. There were no consistent treatment-related changes in laboratory, vital sign or ECG safety parameter values in either study.
| DISCUSSION
MK-1293 is an insulin glargine being developed for the treatment of interval. In Study A, the use of a replicate design also permitted assessment of within-subject day-to-day PK and PD variability in T1D subjects.
Historically, insulin glargine PK has been assessed with nonspecific insulin immunoassays. This has precluded rigourous PK assessment in T1D subjects because of interference from exogenous insulin, and has necessitated calculated adjustment for endogenous insulin in healthy subjects. However, insulin glargine PK can now be assessed without interference from other insulins using an LC-MS/ MS-based approach. [7] [8] [9] After s.c. administration, parent insulin glargine is metabolized to its M1 and M2 metabolites. 23, 24 Although all 3 have similar receptor-level potency, 25 M1 is the dominant circulating insulin glargine species after s.c dosing and is the principle mediator of therapeutic effects, while parent glargine and M2 circulate at very low to unquantifiable concentrations. 8, 9 Therefore, PK comparison in these studies was based on LC-MS/MS-quantified M1 concentrations. In both studies, for all treatment comparisons, M1 PK profiles were closely aligned throughout the 30-hour (Study A) or 24-hour (Study B) assessment period, GMRs for primary (M1 AUC and C max ) and secondary (M1 AUC 0-12 and AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ) PK endpoints were close to 1.0 (range: 0.92-1.02), and pre-specified similarity criteria (90% CIs of GMR between 0.80, 1.25) were met for both primary endpoints. Within-subject PK variability (% CV), assessed in Study A, was also similar between MK-1293 and Lantus.
The euglycaemic clamp platform is long established as the optimal approach for characterizing the PD profile of pharmacologic insulins and is recommended by the EMA for assessing pharmacologic similarity between insulin products. 3 Metrics characterizing accuracy and precision relative to clamp target glucose concentration confirmed high quality clamping in both studies. For both studies and all treatment comparisons, GIR profiles were closely aligned throughout the 24-to 30-hour assessment periods, arithmetic mean ratios for all primary GIR endpoints (GIR-AUC 0-24 , GIR-AUC 0-12 , GIR-AUC 12-24 , GIR max ) were close to 1.0 (range: 0.90-1.03), and pre-specified similarity criteria were met for each of these primary endpoints. Consistent with PK, MK-1293 within-subject PD variability (% CV), assessed in Study A, was also similar to that of Lantus. The duration of action of MK-1293, assessed in T1D subjects in Study A, was also similar to that of Lantus and was greater than 30 hours in the majority of subjects.
Over the first 12 hours after dosing in both studies, M1 exposure (AUC 0-12 ) and PD effect (GIR-AUC 0-12 ) were slightly lower for MK-1293 compared to Lantus. However, as these differences were small (mean treatment ratios ≥0.90) and protocol-specified similarity criteria were met for all comparisons, these observations do not alter the conclusion of PK and PD similarity between MK-1293 and Lantus. Phase III studies in T1D 5 and T2D 6 subjects demonstrating equivalent HbA1c reduction at highly similar doses indicate that any minor PK and PD differences that may exist between MK-1293 and Lantus are not clinically impactful.
Overall, these studies have demonstrated a high degree of PK and PD similarity between MK-1293 and Lantus in both T1D patients and healthy subjects. Given the strong relationship between insulin pharmacology and glycaemic efficacy, these data provide evidence that the clinical efficacy profile of MK-1293 is similar to that of Lantus, 3 an expectation that is confirmed by the results of Phase III studies in T1D 5 and T2D 6 subjects.
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